Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Keymed Biosciences Co.Ltd87 enrolled

Overview

This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313. The dose escalation part will determine the MTD of CM313 in subjects with relapsed and/or refractory multiple myeloma (RRMM) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design). The dose expansion part includes two cohorts. Cohort 1 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Dexamethasone in subjects with RRMM. Cohort 2 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Rd regimen (Lenalidomide/Dexamethasone) in subjects with RRMM or newly diagnosed MM (NDMM).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Myeloma Lymphoma

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Dose escalation: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies and subjects with recurrent and refractory lymphoma. * Dose expansion\_cohort 1: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies. * Dose expansion\_cohort 2: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies, or subjects with NDMM. * For MM: Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria. * For MM: Serum monoclonal paraprotein (M-protein) level greater than or equal to (\>=) 0.5 gram per deciliter (g/dL) or urine M-protein level \>=200 milligram per 24 hours (mg/24 h) or light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain (FLC) \>= 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio. * Eastern Cooperative Oncology Group (ECOG) performance status score \<＝2. * Women of childbearing potential and male subjects must agree to remain abstinent or use contraceptive methods as defined by the protocol. * Side effects of any prior therapy or procedures for any medical condition has recovered to NCI-CTCAE v.5.0 Grade ≤ 1. Key Exclusion Criteria: * Previous treatment with any anti-CD38 therapy. * Subjects with concurrent plasma cell leukemia. * Received a cumulative dose of corticosteroids equivalent to greater than or equal to ( \>=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication). * Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose. * Received an allogenic stem cell transplant or an autologous stem cell transplant within 3 months before first dose of study drug. * Central nervous system (CNS) involvement. * The forced expiratory volume in one second (FEV1)\<60%.

Locations (3)

Beijing Chao-Yang Hospital, Capital Medical University (West Branch)

Beijing, Beijing Municipality, China

RECRUITING

Beijing Chao-Yang Hospital

Beijing, Beijing Municipality, China

RECRUITING

Peking University Third Hospital

Beijing, Beijing Municipality, China

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)

Time frame: Up to 21 days after the first dose

Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0

Time frame: Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier

Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients

ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.

Time frame: Up to 24 months

Secondary Outcomes

Dose escalation: AUC to the last quantifiable concentration [AUC(0-last)], over the dosing interval [AUC(0-tau)], extrapolated to infinity [AUC(0-inf), time to Cmax (tmax), apparent half-life (t1/2), systemic clearance (CL).

Time frame: 21 days after the first dose

Dose escalation and Dose expansion: AUC(0-last), AUC(0-tau), Cmax, t1/2, systemic clearance (CL), volume of distribution (Vz, Vss), minimum concentration (Cmin), Ctrough, accumulation ratios for Cmax and AUC(0-tau) for multiple doses

Time frame: up to 24 months

Dose escalation and Dose expansion: Incidence of anti-CM313

Time frame: up to 24 months

Dose escalation: Overall Response Rate (ORR)

ORR is defined as the proportion of participants who have a partial response (PR) or better according to the IMWG criteria.

Time frame: up to 24 months

Dose escalation and Dose expansion: Clinical Benefit Rate (CBR)

CBR is defined as the proportion of participants who have a minimal response (MR) or better according to the IMWG criteria.

Time frame: up to 24 months

Dose escalation and Dose expansion: Duration of Response (DOR)

DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of PD, per IMWG criteria.or better according to the IMWG criteria.

Time frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)

Dose escalation and Dose expansion: Time to Response (TTR)

TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.

Time frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)

Dose escalation and Dose expansion: Progression-Free Survival (PFS)

PFS is defined as time from date of first dose of study drug to date of first documented PD, per IMWG criteria, or death due to any cause, whichever occurs first.

Time frame: up to 24 months

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Overview

Conditions

Interventions

Eligibility

Locations (3)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts